DelistingMay 12, 2026, 04:52 PM
BIO-key Delisted from Nasdaq, Moves to OTC Markets
AI Summary
BIO-key International, Inc. announced its common stock will be suspended from trading on the Nasdaq Capital Market effective May 13, 2026, and will subsequently trade on OTC Markets under the ticker "BKYI". The delisting is due to non-compliance with Nasdaq's $1 minimum bid price rule and the failure to file its Annual Report on Form 10-K for the year ended December 31, 2025. The company intends to appeal the decision to a Nasdaq Hearings Panel and expressed confidence in its business trajectory, projecting 1H'26 revenues to rise 50% to $5M and achieve profitability.
Key Highlights
- BIO-key common stock suspended from Nasdaq trading effective May 13, 2026.
- Delisting due to failure to meet $1 bid price rule and not filing 2025 Form 10-K.
- Shares will commence trading on OTC Markets under "BKYI" on May 13, 2026.
- Company plans to appeal Nasdaq's delisting determination to a Hearings Panel.
- Forecasts 1H'26 revenues to increase 50% to $5M from $3.3M in 1H'25.
- Expects 1H'26 profitability, contrasting with a $1.9M net loss in 1H'25.
- 1H'26 cash position projected to remain consistent with year-end 2025.
Price Impact
More from BKYI